| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 837344 | 三元基因 | 30.72 | -3.64% | 2.94万 | 9044.53万 | | 002773 | 康弘药业 | 42.26 | -3.38% | 11.33万 | 4.81亿 | | 430047 | 诺思兰德 | 28.23 | -3.16% | 8.74万 | 2.50亿 | | 833575 | 康乐卫士 | 17.80 | -2.57% | 5.20万 | 9287.66万 | | 000534 | 万泽股份 | 16.90 | -1.74% | 18.96万 | 3.20 Z | | 300841 | 康华生物 | 84.77 | -1.70% | 4.19万 | 3.55亿 | | 600211 | 西藏药业 | 46.04 | -1.62% | 9.87万 | 4.54亿 | | 688163 | 赛伦生物 | 25.23 | -1.60% | 1.79万 | 4519.15万 | | 688293 | 奥 ...

中国经济网北京8月20日讯诺唯赞(688105.SH)今日收报25.49元，跌幅1.54%。目前该股处于破发状态。 诺唯赞首次公开发行股票募集资金总额为22.01亿元，扣除发行费用后，募集资金净额为21.09亿元。诺 唯赞最终募集资金净额比原计划多9.07亿元。诺唯赞于2021年11月9日披露的招股书显示，该公司拟募 集资金12.02亿元，分别用于公司总部及研发新基地项目、营销网络扩建项目、补充流动资金。 诺唯赞首次公开发行股票的发行费用合计9137.98万元，华泰联合证券有限责任公司获得保荐及承销费 用7263.92万元。 根据诺唯赞发布的首次公开发行股票科创板上市公告书，保荐机构安排相关子公司华泰创新投资有限公 司(以下简称"华泰创新")参与本次发行战略配售，跟投比例为本次公开发行数量的3%，即120.03万股。 华泰创新获配股票的限售期为24个月，限售期自本次公开发行的股票在上交所上市之日起开始计算。 诺唯赞于2021年11月15日在上交所科创板上市，发行数量为4001.00万股，发行价格为55.00元/股，保荐 机构(主承销商)为华泰联合证券有限责任公司，保荐代表人为王正睿、李皓。 ...

Core Viewpoint - Nanjing Nuotai Zansheng Biotechnology Co., Ltd. has been established with a registered capital of 20 million yuan, focusing on various biotechnological developments [1] Company Summary - The company is involved in the research and development of bio-based materials, industrial enzyme preparations, biological feed, and biochemicals [1] - Shareholding structure indicates that ST Nuotai (688076) and Nuowezan (688105) are among the co-owners of the new company [1]

Group 1: Company Innovations and Achievements - NuoVant has made significant progress with its Alzheimer's disease blood testing product, achieving installations in over 270 hospitals and formal admissions in over 50 hospitals as of June 30 [2] - NuoVant received the "2025 Outstanding Medical Technology Innovation Award" for its high-sensitivity blood test innovation for Alzheimer's disease at the recent 14th Finance Summit [2] - The company has established a global marketing network covering North America, Europe, Southeast Asia, Latin America, and Oceania, with warehouses in the US, Hungary, and Singapore to expedite order delivery [2] Group 2: Industry Growth and Economic Impact - Nanjing's high-tech industry accounted for 55.8% of the city's industrial output value in the first half of the year, with high-tech manufacturing value added increasing by 6.8% year-on-year [1] - The biopharmaceutical industry in Nanjing is a core component of the city's innovative industrial cluster, with the number of approved drugs ranking among the top five in major cities nationwide [3] - The low-altitude economy in Nanjing has seen explosive growth, with the number of drone takeoff and landing sites increasing from 47 to 266, a 466% year-on-year increase [6] Group 3: Collaborative Efforts and Future Directions - Nanjing has established 26 innovation consortia across various sectors, including low-altitude economy, rail transportation, artificial intelligence, and biomedicine, to foster collaboration between industry, academia, and research [8] - The city is actively promoting the development of the low-altitude economy through policy support and the establishment of a comprehensive development framework [6] - Companies like Hongguang General Aviation are focusing on expanding their market share in the drone recovery system, indicating a trend of collaboration within the industry to drive growth [7]

Group 1 - The company announced a share repurchase plan with a total expected amount between 5 million and 10 million RMB [1] - The repurchase period is set from June 19, 2025, to June 18, 2026 [1] - The repurchase is intended for employee stock ownership plans or equity incentives [1] Group 2 - As of July 31, 2025, the company has not yet implemented any share repurchases [1] - The maximum repurchase price is capped at 30 RMB per share [1] - The company will adhere to relevant regulations and disclose progress on the repurchase plan [2]

Core Viewpoint - The company, Novozymes, announced that as of July 31, 2025, it has not yet implemented a share buyback program [2] Summary by Relevant Sections - Company Announcement - Novozymes released a statement indicating that it has not executed any share repurchase as of the specified date [2]

格隆汇8月1日丨诺唯赞(688105.SH)公布，截至2025年7月31日，公司尚未实施股份回购。 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-031 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688105 证券简称：诺唯赞 公告编号：2025-031 二、回购股份的进展情况 截至 2025 年 7 月 31 日，公司尚未实施股份回购。 三、其他事项 | 回购方案首次披露日 | 2025/6/20 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 6 6 月 | 月 | 19 | 日~2026 | 年 | 18 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计 ...

7月30日，医疗器械行业下跌0.38%，今日主力资金流出4.36亿元，成分股41只上涨，56只下跌。 主力资金净流出居前的分别为诺唯赞（1345.21万元）、翔宇医疗（1328.4万元）、山东药玻（1264.96 万元）、ST凯利（1228.57万元）、之江生物（1055.64万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300869康泰医学20.489.647210.99万元7.05%2300760 迈瑞医疗237.962.655584.03万元1.73%3002432九安医疗39.41.184117.95万元9.47%4600587新华医疗 16.813.382981.82万元5.89%5688050爱博医疗77.471.552538.28万元5.85%6300314戴维医疗 14.652.092318.76万元5.67%7300453三鑫医疗8.851.491781.91万元11.83%8300677英科医疗 33.965.51375.80万元1.21%9688029南微医学84.90.981371.50万元3.24%10300529健帆生物 24.370.911339.14万元2.86% 来 ...

Economic Overview - Nanjing's GDP for the first half of the year reached 917.18 billion yuan, with a year-on-year growth of 5.3% [1] - The industrial added value above designated size grew by 6.2% year-on-year, with 30 out of 37 major industrial sectors showing growth, resulting in a growth coverage of 81.1% [2] Industrial Growth - The production of green and smart products saw significant increases, with new energy vehicles, integrated circuits, and industrial robots growing by 45.0%, 22.1%, and 44.2% respectively [2] - The industrial robot market in China experienced an overall sales growth of 11.6% year-on-year, with domestic robots' market penetration increasing by 2 percentage points [3] Service Sector Performance - The revenue of service enterprises above designated size reached 351.22 billion yuan from January to May, marking a year-on-year increase of 3.1% [4] - The information transmission, software, and IT service sectors saw a revenue growth of 10.3%, with emerging industries like internet information services growing by 17.4% [4] High-tech Industry Development - High-tech industries accounted for 55.8% of the total industrial output value, with high-tech manufacturing increasing by 6.8% year-on-year [8] - Specific sectors such as pharmaceutical manufacturing and aerospace equipment manufacturing reported growth rates of 11.6% and 18.5% respectively [8] International Expansion - Nanjing's biopharmaceutical companies are increasingly focusing on international markets, with significant orders and collaborations established globally [10][11] - Companies like Tuokang Robotics reported a 40% revenue growth in the first half of the year, driven by logistics and overseas market expansion [12] Innovation and Technology - Nanjing's innovation landscape is highlighted by advancements in satellite communication systems and autonomous robots, contributing to the region's technological prowess [13] - The collaboration between local companies and international partners is enhancing the competitiveness and brand influence of Nanjing's products [10][11]